-
Something wrong with this record ?
Bringing to Light the Importance of the miRNA Methylome in Colorectal Cancer Prognosis Through Electrochemical Bioplatforms
E. Povedano, V. Ruiz-Valdepeñas Montiel, R. Sebuyoya, RM. Torrente-Rodríguez, M. Garranzo-Asensio, A. Montero-Calle, JM. Pingarrón, R. Barderas, M. Bartosik, S. Campuzano
Language English Country United States
Document type Journal Article
- MeSH
- Biosensing Techniques * methods MeSH
- Epigenome MeSH
- Nucleic Acid Hybridization methods MeSH
- Colorectal Neoplasms * diagnosis genetics MeSH
- Humans MeSH
- MicroRNAs * genetics analysis MeSH
- Prognosis MeSH
- Antibodies genetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
This work reports the first electrochemical bioplatforms developed for the determination of the total contents of either target miRNA or methylated target miRNA. The bioplatforms are based on the hybridization of the target miRNA with a synthetic biotinylated DNA probe, the capture of the formed DNA/miRNA heterohybrids on the surface of magnetic microcarriers, and their recognition with an antibody selective to these heterohybrids or to the N6-methyladenosine (m6A) epimark. The determination of the total or methylated target miRNA was accomplished by labeling such secondary antibodies with the horseradish peroxidase (HRP) enzyme. In both cases, amperometric transduction was performed on the surface of disposable electrodes after capturing the resulting HRP-tagged magnetic bioconjugates. Because of their increasing relevance in colorectal cancer (CRC) diagnosis and prognosis, miRNA let-7a and m6A methylation were selected. The proposed electrochemical bioplatforms showed attractive analytical and operational characteristics for the determination of the total and m6A-methylated target miRNA in less than 75 min. These bioplatforms, innovative in design and application, were applied to the analysis of total RNA samples extracted from cultured cancer cells with different metastatic profiles and from paired healthy and tumor tissues of patients diagnosed with CRC at different stages. The obtained results demonstrated, for the first time using electrochemical platforms, the potential of interrogating the target miRNA methylation level to discriminate the metastatic capacities of cancer cells and to identify tumor tissues and, in a pioneering way, the potential of the m6A methylation in miRNA let-7a to serve as a prognostic biomarker for CRC.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006708
- 003
- CZ-PrNML
- 005
- 20240423155442.0
- 007
- ta
- 008
- 240412s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.analchem.3c05474 $2 doi
- 035 __
- $a (PubMed)38348822
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Povedano, Eloy $u Departamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, Pza. de las Ciencias 2, Madrid 28040, Spain
- 245 10
- $a Bringing to Light the Importance of the miRNA Methylome in Colorectal Cancer Prognosis Through Electrochemical Bioplatforms / $c E. Povedano, V. Ruiz-Valdepeñas Montiel, R. Sebuyoya, RM. Torrente-Rodríguez, M. Garranzo-Asensio, A. Montero-Calle, JM. Pingarrón, R. Barderas, M. Bartosik, S. Campuzano
- 520 9_
- $a This work reports the first electrochemical bioplatforms developed for the determination of the total contents of either target miRNA or methylated target miRNA. The bioplatforms are based on the hybridization of the target miRNA with a synthetic biotinylated DNA probe, the capture of the formed DNA/miRNA heterohybrids on the surface of magnetic microcarriers, and their recognition with an antibody selective to these heterohybrids or to the N6-methyladenosine (m6A) epimark. The determination of the total or methylated target miRNA was accomplished by labeling such secondary antibodies with the horseradish peroxidase (HRP) enzyme. In both cases, amperometric transduction was performed on the surface of disposable electrodes after capturing the resulting HRP-tagged magnetic bioconjugates. Because of their increasing relevance in colorectal cancer (CRC) diagnosis and prognosis, miRNA let-7a and m6A methylation were selected. The proposed electrochemical bioplatforms showed attractive analytical and operational characteristics for the determination of the total and m6A-methylated target miRNA in less than 75 min. These bioplatforms, innovative in design and application, were applied to the analysis of total RNA samples extracted from cultured cancer cells with different metastatic profiles and from paired healthy and tumor tissues of patients diagnosed with CRC at different stages. The obtained results demonstrated, for the first time using electrochemical platforms, the potential of interrogating the target miRNA methylation level to discriminate the metastatic capacities of cancer cells and to identify tumor tissues and, in a pioneering way, the potential of the m6A methylation in miRNA let-7a to serve as a prognostic biomarker for CRC.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mikro RNA $x genetika $x analýza $7 D035683
- 650 _2
- $a epigenom $7 D000081122
- 650 _2
- $a hybridizace nukleových kyselin $x metody $7 D009693
- 650 _2
- $a protilátky $x genetika $7 D000906
- 650 12
- $a kolorektální nádory $x diagnóza $x genetika $7 D015179
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a biosenzitivní techniky $x metody $7 D015374
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Ruiz-Valdepeñas Montiel, Víctor $u Departamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, Pza. de las Ciencias 2, Madrid 28040, Spain $1 https://orcid.org/0000000288651531
- 700 1_
- $a Sebuyoya, Ravery $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic $u National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Kamenice 5, Brno 625 00, Czech Republic
- 700 1_
- $a Torrente-Rodríguez, Rebeca M $u Departamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, Pza. de las Ciencias 2, Madrid 28040, Spain
- 700 1_
- $a Garranzo-Asensio, Maria $u Chronic Disease Programme, UFIEC, Institute of Health Carlos III, Majadahonda, Madrid 28220, Spain
- 700 1_
- $a Montero-Calle, Ana $u Chronic Disease Programme, UFIEC, Institute of Health Carlos III, Majadahonda, Madrid 28220, Spain
- 700 1_
- $a Pingarrón, José M $u Departamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, Pza. de las Ciencias 2, Madrid 28040, Spain $1 https://orcid.org/0000000322711383
- 700 1_
- $a Barderas, Rodrigo $u Chronic Disease Programme, UFIEC, Institute of Health Carlos III, Majadahonda, Madrid 28220, Spain $1 https://orcid.org/0000000335397469
- 700 1_
- $a Bartosik, Martin $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, Czech Republic
- 700 1_
- $a Campuzano, Susana $u Departamento de Química Analítica, Facultad de CC. Químicas, Universidad Complutense de Madrid, Pza. de las Ciencias 2, Madrid 28040, Spain $1 https://orcid.org/0000000299286613
- 773 0_
- $w MED00000337 $t Analytical chemistry $x 1520-6882 $g Roč. 96, č. 11 (2024), s. 4580-4588
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38348822 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155438 $b ABA008
- 999 __
- $a ok $b bmc $g 2080981 $s 1216475
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 96 $c 11 $d 4580-4588 $e 20240213 $i 1520-6882 $m Analytical chemistry $n Anal Chem $x MED00000337
- LZP __
- $a Pubmed-20240412
